6月3日，科伦博泰生物盘中下跌3.17%，报389.4港元，成交额6461.95万港元。
消息面上，科伦系业绩全面失速的影响仍在持续发酵。科伦博泰虽营收增长6.5%至20.58亿元，但净亏损从2.67亿元扩大至3.82亿元，主因授权及里程碑收入大幅减少、研发费用高企。同时，港交所披露显示董事长刘革新于5月26日至28日连续减持合计约25.73万股，进一步加剧市场担忧。该股此前因ASCO年会数据利好及机构上调目标价连续上涨后积累了较多获利盘，近期持续回调，股价已自高点回落逾18%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.